APS:CC

Quote

Short

News

Articles

Message Board

Aptose Biosciences Inc. (TSXC : APS:CC ) News

News Releases

APS:CC News Releases

June 15, 2026 07:30:00 am

GlobeNewswire

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

May 13, 2026 05:00:00 pm

GlobeNewswire

Aptose Reports First Quarter 2026 Results

April 30, 2026 07:30:00 am

GlobeNewswire

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

March 31, 2026 05:22:58 pm

GlobeNewswire

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights

March 31, 2026 01:13:18 pm

SeekingAlpha

Aptose Biosciences Inc. (APS:CA) Shareholder/Analyst Call Prepared Remarks Transcript

March 23, 2026 07:30:00 am

GlobeNewswire

Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement

March 19, 2026 07:30:00 am

GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical

February 24, 2026 07:00:00 am

GlobeNewswire

Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders

December 19, 2025 05:05:31 pm

GlobeNewswire

Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

December 06, 2025 08:00:00 am

GlobeNewswire

Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account